MYD88 and incontinentia pigmenti: Staudt’s team has proposed the ‘gene heptad’ that classifies DLBCL with co-mutations in MYD88 L265P and CD79B as the MCD type, while Shipp’s team ‘gene quintet’ suggests that C5 corresponds to the MCD type, hence IP-LBCL is also referred to as MCD/C5 subtype lymphomas.